Department of Psychiatry, Meram Faculty of Medicine, Necmettin Erbakan University , Konya, Turkey .
Breastfeed Med. 2019 Mar;14(2):131-132. doi: 10.1089/bfm.2018.0197. Epub 2018 Nov 29.
Selective serotonin reuptake inhibitors (SSRIs), especially sertraline and paroxetine, are first-line antidepressants in the treatment of postpartum depression in breastfeeding women as these drugs are well tolerated by most breastfed infants. Although some women with these diagnoses require additional antidepressants to SSRIs, the safety of combined usage of SSRIs and mirtazapine is currently unknown. This report includes short-term safety data of breastfed infants exposed to paroxetine plus low-dose mirtazapine.
选择性 5-羟色胺再摄取抑制剂（SSRIs），尤其是舍曲林和帕罗西汀，是母乳喂养妇女产后抑郁症治疗的一线药物，因为这些药物大多数情况下能被母乳喂养的婴儿良好耐受。尽管一些患有这些疾病的妇女需要在 SSRIs 基础上增加使用其他抗抑郁药，但目前尚不清楚 SSRIs 和米氮平联合使用的安全性。本报告包括了暴露于帕罗西汀加低剂量米氮平的母乳喂养婴儿的短期安全性数据。
